Field Randomization of Nerinetide (NA-1) Therapy in Early Responders (FRONTIER)

  • STATUS
    Recruiting
  • End date
    Dec 11, 2023
  • participants needed
    586
  • sponsor
    NoNO Inc.
Updated on 11 July 2022
Investigator
Michael Tymianski, MD PhD
Primary Contact
Royal Columbian Hospital (1.7 mi away) Contact
+3 other location

Summary

The purpose of this study is to determine whether nerinetide (NA-1) is effective in reducing global disability in patients with acute cerebral ischemia if administered early after symptom onset.

Description

Nerinetide (NA-1) is being developed as an emergency drug aimed at reducing global disability in patients with acute cerebral ischemia if administered early after symptom onset.

The primary objective is to determine the efficacy of nerinetide in reducing global disability in patients with acute stroke. The secondary objectives are to determine the efficacy of nerinetide in reducing functional dependence, reducing mortality rate, reducing worsening of stroke, improving neurological outcome and improving activities of daily living.

The leading safety objectives are to determine the effect of administering a target dose of 2.60 mg/kg (up to a maximum dose of 270 mg) IV infusion of nerinetide within three hours of symptom onset by paramedics in the field on serious adverse events and 90-day mortality.

This trial is a multicenter, randomized, double-blind, placebo-controlled, single dose study initiated prehospital in the ambulance. It is being conducted using Emergency Medical Services (EMS) in Canada. Subjects with suspected acute stroke will be identified in the field by trained paramedics using the approved stroke protocol in use by the local EMS system, and further screened for eligibility and approval by an on-call trial physician. The paramedics will administer the study drug. Upon arrival at the emergency department, subjects will receive standard-of-care.

An Independent Data Monitoring Committee will perform safety reviews of the clinical data.

Details
Condition Acute Cerebral Ischemia
Treatment Placebo, NA-1, Nerinetide (NA-1)
Clinical Study IdentifierNCT02315443
SponsorNoNO Inc.
Last Modified on11 July 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Provisional diagnosis of acute stroke as identified by paramedics using the local stroke triage tool
Respiratory rate 12-24 breaths per minute
Oxygen saturation ≥ 90% on room air
Systolic blood pressure < 90 or > 220 mmHg
Weight 45-120 kg
Last seen in usual state of health less than 3 hours before anticipated study drug initiation
Independently ambulatory with or without devices prior to event
LAMS score of 2-5 for at least 15 minutes and remains 2-5 at time of randomization

Exclusion Criteria

Lack of IV access
Canadian Triage and Acuity Scale Level 1 and/or uncorrected airway, breathing or significant circulatory problem
Blood sugar < 3 mmol/L (< 55 mg/dL)
Seizure at onset of symptoms or observed by paramedic
Glasgow coma score of <10
Major head trauma in the last three months
Recent stroke in the last three months
Known or presumptive signs of pregnancy or breastfeeding
Prisoner
Long term care facility resident
Known advance directive to not resuscitate
Known participation in a clinical trial with an investigational drug or device within 30 days preceding this trial
Pre-existing neurologic, psychiatric, or advanced systemic condition that would preclude obtaining the neurological or functional outcome evaluations
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note